Aspirin dumping
This article was originally published in The Tan Sheet
Executive Summary
U.S. Customs service will impose antidumping duties on bulk aspirin imports from China following a June 22 ITC determination the imports threaten U.S. industry with material injury. In an amended final determination June 21, the ITA revises previously announced weighted-average dumping margins for two Chinese firms: Shandong Xinhua Pharmaceutical Factory, 16.5% (previously 42.8%) and Jilin Pharmaceutical, 10.9% (previously 4.7%). The PRC-wide rate of 144% is unchanged (1"The Tan Sheet" May 29, In Brief)
You may also be interested in...
Chinese bulk aspirin
Shandong Xinhua Pharmaceutical did not make bulk aspirin sales "below normal value" from July 1, 2002 through June 30, 2003, the International Trade Administration says April 8. ITA therefore preliminarily finds that an antidumping order for the Chinese firm should be revoked, and invites comment before publication of final notice. The Department of Commerce originally published an antidumping order on Shandong Xinhua bulk aspirin in July 2000 (1"The Tan Sheet" July 3, 2000, p. 2)...
Chinese bulk aspirin
Jilin Henghe Pharmaceutical and Shandong Xinhua Pharmaceutical did not sell bulk aspirin in the U.S. "below normal value" from July 1, 2001 through June 30, 2002, International Trade Administration says Aug. 13. ITA determines no antidumping duties should be imposed on the two Chinese companies; antidumping margin of 144% applicable to other bulk aspirin exporters based in the People's Republic of China remains unchanged. In July 2000, U.S. Customs service imposed antidumping duties of 16.5% on Shandong, 10.9% on Jilin (1"The Tan Sheet" July 3, 2000, p. 2)...
Chinese aspirin
Antidumping margin of 144% applicable to all but two bulk aspirin exporters in the People's Republic of China, the International Trade Administration says in a final determination published in the Federal Register May 25. ITA assigns weighted-average dumping margins of 42.8% to Shandong Xinhau Pharmaceutical Factory and 4.7% to Jilin Pharmaceutical. The case now goes to the International Trade Commission, which will issue an antidumping order if it determines Chinese bulk aspirin imports are materially injurious, or threaten material injury, to U.S. industry. The investigation was requested by Cranbury, N.J.-based bulk aspirin maker Rhodia (1"The Tan Sheet" June 14, 1999, p. 9)